BEST WORLD INTERNATIONAL LIMITED

Company Registration No. 199006030Z

BEST WORLD INTERNATIONAL LIMITED STRONGLY REFUTES BONITAS RESEARCH REPORT

The Board of Directors (the "Board" or "Directors") of Best World International Limited (the "Company" and together with its subsidiaries, the "Group") refers to the short seller report released by Bonitas Research ("Bonitas") on 24 April 2019 (the "Report") regarding the Group's operations in China in 2017.

The Report contains false and defamatory allegations intended to undermine the reputations of the Group and its senior management, cause a loss of confidence in the Group and inflict damage on the price of the shares of the Company (the "Shares") to financially benefit Bonitas.

Bonitas is a professional short seller and has openly stated in the Report that it would profit from the decline in the Company's share price. The Company strongly urges its shareholders and potential investors not to be deceived by the Report, which has undermined confidence in the Group and destroyed the value that the Company has created for its shareholders over the years.

The Company would also like to announce that the Company and its co-founders, Mdm. Dora Hoan Beng Mui ("Mdm. Hoan") and Mdm. Doreen Tan Nee Moi (collectively, the "Founders"), have on 3 May 2019 commenced defamation proceedings against Bonitas and its founder in the High Court of Singapore.

(A) The Group's Former Export Business in China

Before the Company responds to the issues raised in the Report, it would be beneficial to provide shareholders with an overview of the Group's Export Model business in China prior to its transition to the Franchise Model in June 2018.

From 2014 to 2018, the Group distributed its "DR's Secret" products, as well as electronic beauty devices ¹, Miraglo microfibre exfoliation products ² and certain other products (collectively, the "**Products**") in China through independent import agents (the "**Import Agents**") under the Export Model. The Import Agents would purchase the Products from the Group as principals, import the Products into China and on-sell the Products to customers throughout China. The Group selected the Import Agents based on a number of criteria, including their capability and experience in product registration, importation and customs clearance in accordance with applicable local rules and regulations, and logistics and related processes.

Under the Export Model, the Import Agents would purchase the Products from the Group based on their expected sales to their customers. Generally, the Import Agents were responsible for importing the Products, customs clearance, warehousing, and receiving and fulfilling orders from customers.

Please refer to www.drs-secret.com/products#device for information on the Group's range of electronic beauty devices.

Please refer to <u>www.miraglo.com.sg/about.html#</u> for information on the Group's Miraglo microfibre exfoliation products.

Under the Export Model, the direct customers of the Group were the Import Agents, who were independent third parties who took ownership of the Products they purchased and bore inventory risk and risk of default by the end customers. The Group recognised export revenue upon delivery or completion of the sale to the Import Agents, being the Group's direct customers. This revenue recognition was in line with the Singapore Financial Reporting Standards ("SFRS") adopted up to 31 December 2017, and the Singapore Financial Reporting Standards (International) ("SFRS(I)"), which was adopted as the accounting standard of the Group on 1 January 2018.

Although the Group worked with and sold its products to a few Import Agents in China under the Export model over the years, it largely worked with one primary Import Agent in promoting its products in China, 长沙百世特威日用品贸易有限公司 (translated in the Report to "Changsha Best Commodity Trading Co., Ltd.") (the "**Primary Import Agent**"). The Company entered into a distribution agreement dated 1 August 2015 (the "**Distribution Agreement**") with the Primary Import Agent, which was automatically renewed annually until it was terminated on 30 September 2018 after the completion of the Group's transition to the Franchise Model in China. Pursuant to the Distribution Agreement, the Primary Import Agent was appointed as the Group's exclusive distributor for certain Products and the Primary Import Agent was not permitted to market or sell any goods or products that competed or conflicted with such Products.

With the transition to the Franchise Model, the role of the Primary Import Agent was replaced by Best World (China) Pharmaceutical Co., Ltd. (全美世界(中國)藥業有限公司) ("**BWL China**"), a wholly-owned subsidiary of the Company. Selected distributors of the Products in China (which were previously the Primary Import Agent's customers) were converted into Franchisees by entering into franchise agreements with the Group.

Shareholders are advised to refer to the Company's announcement dated 23 February 2019 for further details of the Group's transition from the Export Model to the Franchise Model in 2018, including the rationale for the transition.

(B) Clarification of untrue statements in the Report

The various issues raised in the Report and the Company's response to the same ("Response") can be summarised as follows and full details of the Company's Response are set out in the Appendix hereto:

1. Independent Review: No Cover-up

Bonitas alleges that the Company had intentionally limited the scope of the independent review (the "**Review**") by PricewaterhouseCoopers Consulting (Singapore) Pte Ltd ("**PwC**")³ to the Group's business in China in 2018 to divert attention from fabricated sales in China in 2017.

Our Response:

It is absurd to allege that the scope of the Review was calculated to conceal the Group's financial statements for the financial year ended 31 December ("FY") 2017 from third party review as:

On 19 March 2019, the Company announced the appointment, in consultation with SGX RegCo, of PwC to conduct an independent review of the Franchise Model adopted by the Group in China in 2018.

- the Review was voluntarily commissioned by the Company in response to the Business Times article published on 18 February 2019 in relation to the Company (the "**Article**")⁴, which focused on the Group's Franchise Model in China in FY2018; and
- (b) the scope of the Review was reviewed and approved by the Audit Committee of the Company (the "Audit Committee") and SGX RegCo.

PwC will report its findings directly to the Audit Committee and SGX RegCo and the Company will publish an executive summary of all key findings of the Review on SGXNet. The Audit Committee and SGX RegCo have the discretion to require the Review to be extended based on the findings made by PwC as the independent reviewer.

2. No Fabrication of Sales

Bonitas alleges that the Company has fabricated at least S\$ 31 million of its sales for FY2017 on the basis that this figure is the difference between the Group's sales to the Primary Import Agent and the Primary Import Agent's cost of goods of skincare products in FY2017.

Our Response:

(a) Differences in the recognition of revenue and costs of goods sold

The Report notes that in FY2017, the Company recorded sales of S\$105.8 million to the Primary Import Agent (the "Group's Relevant Sales"), while the Primary Import Agent recorded costs of goods sold (the "Primary Import Agent's COGS") of S\$74.6 million, and concludes that the Company "overstated its 2017 China skin care sales by at least S\$31 million".

- (i) The difference between the Group's Relevant Sales and the Primary Import Agent's COGS does not prove fabrication of sales at all, as revenue and costs of goods sold ("COGS") are recognised in the financial statements of companies at different points in time.
- (ii) The difference in the Group's Relevant Sales and the Primary Import Agent's COGS only indicates that the Primary Import Agent did not sell all the Products it purchased from the Group in FY2017 in the same financial year, not that any sales were fabricated.
- (iii) The Report in fact states that the Primary Import Agent reported an inventory balance of S\$33.7 million at the end of FY2017⁵, which shows that Bonitas was aware that the Primary Import Agent did not sell all of the Products it purchased from the Group before the end of FY2017.

Based on the foregoing, Bonitas' allegation of purported fabricated sales is entirely incorrect and premised on a misapplication of basic accounting principles.

On 23 February 2019, the Company released an announcement to clarify matters in the Article.

There is no assurance that the inventory balance of the Primary Import Agent at the end of FY2017, as stated in the Report, is accurate.

(b) Audit procedures

The Company categorically rejects any accusation that it fabricated sales. All sales have been properly documented and accounted for, and the Group's financial statements are subject to independent audit.

Testing of revenue: As part of their audit of the financial statements of the Group for FY2017, Ernst & Young LLP ("EY") has tested the revenue of the Group in accordance with the Singapore Standards of Auditing. EY provided an unqualified opinion in respect of the audited financial statements of the Group for FY2017.

Cash balance confirmation: EY has independently obtained confirmations from the Group's banks confirming the Group's cash balances as at 31 December 2017.

The cash balances of the Group as at 31 December 2017 should reassure shareholders that the sales recorded by the Group in FY2017 were not fabricated.

3. The Primary Import Agent is an Independent Party

Bonitas alleges that the Primary Import Agent (referred to as "Changsha Best" in the Report), the Group's major customer in China for FY2017, was secretly controlled by the Company's management in an attempt to cast doubt on the sales made by the Group to it.

Our Response:

(a) The Primary Import Agent is an independent third party

The Report presents no evidence to establish any link between the Primary Import Agent and the Company, the Directors, the substantial shareholder of the Company or their associates.

The Company confirms that the Primary Import Agent, a company incorporated in China, is independent and not related to the Group. None of the Group, the Directors, the substantial shareholders of the Company or their associates have had any direct or indirect shareholding interests, directorship or management role in the Primary Import Agent.⁶

The Company has never been involved in or had any control over the Primary Import Agent's operations. The Group initially engaged the Primary Import Agent in 2015 to assist with the importation of small volumes of the Products to China. As the business relationship developed, the Group gradually increased its business dealings with the Primary Import Agent, as the Primary Import Agent proved itself with its reliable service, and its cooperation with the Group to promote the Products in China in order to create a market and increase demand for the Products in China. Please refer to the section entitled "Transition from Export Model to Franchise Model in China" of the Company's clarification announcement dated 23 February 2019 for further information on the cooperation between the Group and the Primary Import Agent.

As part of the initial scope of the Review, PwC will review the independence of the Primary Import Agent.

Shareholders may conduct a search against the Primary Import Agent on the National Enterprise Credit Information Publicity System at http://www.gsxt.gov.cn/index.html.

(b) The Group's sales and profits have increased since the transition to the Franchise Model

Bonitas claims that the Company's management secretly controlled and created the Primary Import Agent in order to fabricate sales and fraudulently overstate the Group's profits in FY2017.

Since the Group's transition to the Franchise Model in June 2018 and the replacement of the Primary Import Agent by BWL China, the Company's sales and profits have increased substantially, as disclosed in the Company's announcement of the Group's unaudited financial statements for the third quarter of FY2018 ("3Q2018")⁷ and fourth quarter of FY2018 ("4Q2018")⁸.

The fact that the Company's sales and profits have increased substantially since the replacement of the Primary Import Agent disproves Bonitas' claim that the Primary Import Agent was created to fabricate sales and inflate profits.

Furthermore, based on PwC's interim update as of 12 April 2019, the Board and the Audit Committee understand that PwC has not identified any matters that may have a material impact on the Group's unaudited financial statements for FY2018. Work on the Review is progressing as at the date of this announcement.

4. The Company does not conduct Direct Selling in China

Bonitas alleges that the Group is conducting direct selling of its skincare products in China without a valid licence.

Our Response:

(a) The Group's distribution strategies

The Company understands that growth in demand for its products requires an effective distribution strategy. Over the years, the Company has adopted various distribution strategies and tailored them to suit the markets in which the Group operates.

The Company takes its compliance obligations seriously, and developed the Franchise Model with advice from its professional advisors. The Company's legal counsel in China, Beijing Dacheng Law Offices, LLP (part of the global law firm Dentons), one of the largest law firms in China, has opined that the business of the Group under the Franchise Model complies with applicable laws and regulations. The Company will seek a separate legal opinion on whether its current distribution model in China constitutes direct selling under the applicable laws and regulations and will make further announcements to update shareholders in due course.

The Company recognises that laws and regulations, as well as the interpretation and application thereof, may change over time and/or in response to current developments. In order to ensure compliance and the security of its business and operations, the Company will continue to review the implementation of the Franchise Model, and will

⁷ Announced by the Company on 8 November 2018.

⁸ Announced by the Company on 26 February 2019.

not hesitate to continue to fine tune and further develop the Franchise Model in order to remain effective and ensure compliance with applicable laws and regulations.

(b) Distribution and commission structure under the Franchise Model

Please refer to pages 17 and 18 of this announcement for information on the Group's distribution and commission structure under the Franchise Model in China.

The Company confirms that:

- (i) the Group did not pay any bonuses to "Member Reps" (as described in the Report) for recruitment of other Member Reps in China or any market in which the Group operates; and
- (ii) the commission structure presented on pages 21 and 23 of the Report is the commission structure applied in the Company's direct selling markets, such as Taiwan and Singapore (amongst others). This commission structure is not applied by the Group in China.

The payment of commissions for sales is not a practice exclusive to direct selling distribution models. Many, if not most, sales models involve the payment of commissions for sales. The fact that commissions are paid for sales achieved does not mean that the Franchise Model constitutes direct selling or a violation of the Administrative Regulations on Commercial Franchise of China.

(c) Alternative distribution models

The Company has received professional advice that the Group's business under the Franchise Model complies with applicable laws and regulations.

However, should there be any change in applicable laws and regulations or interpretation thereof which results in the Group's Franchise Model in China being found to require a direct selling licence, the Group would cooperate with the relevant authorities to expand the coverage of the Group's existing Direct Selling Licence (as defined below)⁹ and transition to a direct selling model in China accordingly.

Prior to the transition to the Franchise Model, the Company had already explored the option of transitioning to a direct selling model in China. The Company believes that it will be able to do so if it becomes necessary without major disruptions to its operations in China.

Alternatively, the Group may also revert to the Export Model formerly adopted in China from 2014 to June 2018.

As disclosed in the announcement on 23 February 2019, the Group does not rely on the direct selling licence it received from Ministry of Commerce of the People's Republic of China in June 2016 covering certain health supplement products over a limited geographical space in China, and the Company had previously considered transitioning from the Export Model to a Direct Selling Model in China, but chose instead to adopt the Franchise Model.

(d) Continued sales of the Products

Regardless of the distribution model adopted for the Products, the intellectual property rights and product registrations and licences in respect of the Products sold in China would remain valid. The Group has invested years to cultivate the market in China for the Products and believes that it would be able to continue to successfully sell the Products in China even under a different distribution model.

5. No Fraud

Bonitas alleges that the Founders engaged in a fraudulent scheme to profit from the Company by grossly overstating the Founders' dividend entitlements and suggesting such dividend payments were made through increasing outstanding payments (i.e., trade and other payables).

Our Response:

(a) Overstatement of dividends

The Company declared \$\$90.9 million of dividends from FY2010 to FY2018. The Report falsely alleges that the Founders received approximately \$\$74.4 million in dividends from FY2010 to FY2018. This would require the Founders to own 81.8% of the Company's shares from FY2010 to FY2018, which is plainly untrue.

The author of the Report has either miscalculated the Founders' collective ownership of the Company, or deliberately misstated the dividend amounts received by the Founders.

(b) Consistent dividend payments

Since 2004, the Company has declared dividends totaling S\$115.3 million, notwithstanding that (i) the Group had total borrowings of only S\$1.4 million as at 31 March 2019¹⁰; and (ii) the Company has not raised any funds from the equity capital markets since October 2005.

The allegation that the Company's sales were fabricated simply does not stand up to the facts, which is that the Company has consistently generated profits; profits which the Company has distributed to its shareholders over the years in line with good corporate governance.

6. Bonitas Fieldwork

Bonitas claims that the Changsha Tianxin BWL Lifestyle Center was closed during business hours from the 20th to 22nd of March 2019.

Our Response:

This claim is incorrect as the Changsha Tianxin BWL Lifestyle Center was open on 20 March 2019. PwC has confirmed to the Company that its employees were at the Changsha Tianxin BWL Lifestyle Center on 20 March 2019 for an arranged visit as part of the Review.

Please refer to Section 8 of the Company's announcement dated 8 May 2019 for the Group's unaudited financial statements for 1Q2019.

(C) Independent Review

The Company has taken note of the position of SGX RegCo that an independent review on the allegations made in the Report should be undertaken. Certain allegations raised in the Report concern the Group's previous financial statements which have been independently audited by two (2) reputable audit firms, RSM Chio Lim LLP ("**RSM**") and EY. Both RSM and EY have not withdrawn their unqualified audit opinions with regard to the Company's financial statements for the periods they have each reviewed, RSM in respect of FY2014 to FY2016 and EY in respect of FY2017, after reviewing the Report and this announcement.

Notwithstanding that the Company has received unqualified audit opinions in respect of the Group's audited financial statements for FY2014 to FY2017, the Company has voluntarily and in consultation with SGX RegCo decided to expand the scope of the Review by PwC¹¹ to include reviews of:

- (a) the Group's sales and inventory flow of the Export Model in China for the period from 1 January 2017 to 31 May 2018¹²; and
- (b) the Group's historical cashflow of the Singapore entities of the Group from 1 January 2017 to 31 December 2018.

In connection with the expanded scope of the Review, the Company will request the Primary Import Agent to provide its audited financial statements for FY2017 to PwC for review.

Based on PwC's interim update as of 12 April 2019, the Board and the Audit Committee understand that PwC has not identified any matters that may have a material impact on the Group's unaudited financial statements for FY2018 ¹³. Work on the Review is progressing as at the date of this announcement.

(D) Share Buybacks

The Board has earmarked and approved the utilisation of part of the Company's cash holdings to repurchase Shares traded on the Singapore Exchange Securities Trading Limited (the "SGX-ST") in accordance with the share buyback mandate approved on 30 April 2018 (the "Share Buybacks"). The Company will commence the Share Buybacks following the announcement of the Company's unaudited financial results for the financial quarter ended 31 March 2019 (the "1Q2019 Results") ¹⁴ and the expiration of the blackout period in relation to the 1Q2019 Results.

The Board believes that the Shares are currently undervalued following the decline in the prices of the Shares since February 2019, and that the recent prices of the Shares are no longer a fair reflection of the underlying value of the Company.

On 19 March 2019, the Company announced the appointment, in consultation with SGX RegCo, of PwC to conduct an independent review of the Franchise Model adopted by the Group in China in 2018.

¹² 31 May 2018 is the last day that the Group recorded sales under the Export Model.

Announced by the Company on 26 February 2019.

¹⁴ Announced by the Company on 8 May 2019.

Accordingly, the Board believes that undertaking Share Buybacks at current Share prices will be an effective use of the Group's cash and will enhance shareholder value by reducing the total number of Shares in circulation and increase the earnings per Share of the Company.

The Company intends to fund the Share Buybacks with the Group's cash in excess of the Group's short and medium term requirements.

(E) Statement to Shareholders

The Company would like to assure its shareholders that it has conducted all areas of its business ethically and in compliance with applicable laws and accounting standards.

The Board is of the view that (a) the explanations contained in this announcement; (b) the Group's audited financial statements for FY2014 to FY2017 (and FY2018, once despatched to shareholders); and (c) the results of the Review, will provide comfort and assurance to the Company's shareholders that the Report is without merit and intended to mislead shareholders and destroy the value of the Shares.

Shareholders and investors are reminded to exercise caution when dealing in the Shares and to refrain from taking any action in respect of their Shares which may be prejudicial to their interests. In the event that shareholders and investors are in doubt when dealing in the Shares, they should consult their legal, financial, tax or other professional adviser(s).

The Company will continue to engage stakeholders in a constructive manner to address any concerns regarding the Group's business practices and financial position.

Any queries relating to this announcement may be directed to:

Gibson, Dunn & Crutcher LLP

Robson LEE Partner

E-mail: RLee@gibsondunn.com

Tel: (65) 6507 3684

BY ORDER OF THE BOARD

Huang Ban Chin Director and Chief Operating Officer 8 May 2019

Appendix

1. Independent Review: No Cover-Up

Bonitas alleges that the Company had intentionally limited the scope of the Review to the Group's business in China in 2018 in an attempt to divert attention from fabricated sales in China in 2017.

Our Response:

(a) The Review was commissioned to answer allegations in the Article

The Company voluntarily commissioned the Review in response to the Article. As the Article focused on the Franchise Model in China, which the Group transitioned to in June 2018, there was no reason for the scope of the Review to be extended to cover the Export Model before 2018.

(b) The scope of the Review was approved by SGX RegCo

The scope of PwC's review was agreed in consultation with SGX RegCo to address concerns raised in the Article. It is absurd for the Report to allege that the Company had any intention of concealing the Group's financial results for FY2017 from third party review.

(c) <u>Financial statements for FY2017 were audited</u>

The Group's financial statements for FY2017 were audited by the Company's independent external auditors, EY¹⁵, who provided an unqualified opinion.

In fact, the historical financial statements of the Group which accounted for the results of the Group's Export Model have been audited by two (2) separate reputable audit firms, (i) RSM from FY2014 to FY2016; and (ii) EY in FY2017. Since the Company's listing in 2004, the Company's auditors have never qualified their audit opinion on the financial statements of the Group.

Both RSM and EY have not withdrawn their unqualified audit opinions with regard to the Company's financial statements for the periods reviewed after reviewing the Report and this announcement.

Please refer to the Company's annual report for FY2017 dated 13 April 2018 for the Group's audited financial statements for FY2017.

2. No Fabrication of Sales

Bonitas alleges that the Company has fabricated at least S\$ 31 million of its sales for FY2017 on the basis that this figure is the difference between the Group's sales to the Primary Import Agent and the Primary Import Agent's cost of goods of skincare products in FY2017.

Our Response:

(a) Differences in the recognition of revenue and costs of goods sold

The Report notes that in FY2017, the Group's Relevant Sales was \$\$105.8 million, while the Primary Import Agent's COGS was \$\$74.6 million.

Based on the figures set out above, Bonitas simply jumps to the conclusion that the Company "overstated its 2017 China skin care sales by at least S\$31 million".

This incorrect and simplistic conclusion can be dismissed as follows:

- (i) The difference between the Group's Relevant Sales and the Primary Import Agent's COGS does not prove fabrication of sales at all, as revenue and cost of goods sold ("COGS") are recognised in the financial statements of companies at different points in time as follows:
 - (A) the Company recognised revenue under the Export Model upon delivery or completion of the sale to the Primary Import Agent in line with SFRS (applied before 31 December 2017) and SFRS(I) (adopted as the accounting standard of the Group on 1 January 2018); and
 - (B) the Primary Import Agent may only record COGS upon the sale of the Products to its end customers.
- (ii) The Group's Relevant Sales and the Primary Import Agent's COGS would only be equal in FY2017 if the Primary Import Agent sold all of the Products it purchased from the Group in FY2017 in the same financial year.
- (iii) The difference in the Group's Relevant Sales and the Primary Import Agent's COGS only indicates that the Primary Import Agent did not sell all of the Products it purchased from the Group in FY2017 in the same financial year, not that any sales were fabricated.
- (iv) The Report in fact states that the Primary Import Agent reported an inventory balance of S\$33.7 million at the end of FY2017, which shows that Bonitas was aware that the Primary Import Agent did not sell all of the Products it purchased from the Group before the end of FY2017.
- (v) The Primary Import Agent purchased more Products than usual in the fourth quarter of FY2017 ("4Q2017") in anticipation of the Group's impending transition to the Franchise Model in FY2018. This was previously disclosed by the Company in its financial results announcements for FY2017 and the first quarter of FY2018 ("1Q2018"), where it was disclosed that the Primary Import

Agent had purchased in 4Q2017 the inventory it required for the first half of FY2018, in anticipation of the transition to the Franchise Model 16.

Based on the foregoing, Bonitas' allegation of purported fabricated sales is entirely incorrect and premised on a misapplication of basic accounting principles.

(b) Audit procedures

The Company categorically rejects any accusation that it fabricated sales. All sales have been properly documented and accounted for, and the Group's financial statements are subject to independent audit.

Testing of revenue: As part of their audit of the financial statements of the Group for FY2017, EY has tested the revenue of the Group in accordance with the Singapore Standards of Auditing, which included:

- (i) performing test of controls over the sales and accounts receivables process for export sales;
- (ii) performing sales cut-off procedures by tracing acknowledged bill of lading and sales sub-ledger two weeks before and after year-end to ensure revenue are recorded in the correct financial period;
- (iii) reviewing significant credit memos issued during the year and subsequent to year-end to identify reversal of sales;
- (iv) performing test of details over a sample of selected revenue transactions by tracing to acknowledged bill of lading; and
- (v) testing the existence of trade receivables from the Primary Import Agent through direct accounts receivables (AR) confirmation and testing the recoverability of such trade receivables.

As mentioned above, EY provided an unqualified opinion in respect of the audited financial statements of the Group for FY2017.

Cash balance confirmations: EY has independently obtained confirmations from the Group's banks of the Group's cash balances as at 31 December 2017.

The cash balances of the Group as at 31 December 2017 should reassure shareholders that the sales recorded by the Group in FY2017 were not fabricated.

12

Please refer to Section 10 of the Company's announcement dated 26 February 2018 of the Group's unaudited financial statements for FY2017 and Section 8 of the Company's announcement dated 14 May 2018 of the Group's unaudited financial statements for 1Q2018.

Shareholders may also refer to **Annex A** to this announcement for a ledger recording the invoice numbers, amounts and dates of the Group's exports to the Primary Import Agent in FY2017. **Annex B** to this announcement sets out a sample of the invoices and export documentation in relation to the sales to the Primary Import Agent in FY2017. The underlying invoices and export documentation will be made available to PwC for the purposes of the Review.

(c) <u>Incorrect exclusion of the COGS of non-skincare Products from calculations which</u> therefore inflated alleged overstated sales by the Group to the Primary Import Agent

The Products sold by the Group to the Primary Import Agent were not limited to skincare products. The Relevant Sales of approximately S\$105.8 million to the Primary Import Agent in FY2017 also consisted of revenue from sales of electronic beauty devices ¹⁷, Miraglo microfibre exfoliation products ¹⁸ and certain other products in China.

Confined to skincare sales, the Group's sales to the Primary Import Agent in China were approximately \$\$86.2 million in FY2017. The other types of products sold to the Primary Import Agent, which are also recorded as revenue to the Group when exported, were incorrectly excluded from the discussion by Bonitas and therefore inflated the alleged overstated sales by the Group to the Primary Import Agent.

3. The Primary Import Agent is an Independent Party

Bonitas alleges that the Primary Import Agent (referred to as "Changsha Best" in the Report), the Group's major customer in China for FY2017, was secretly controlled by the Company's management in an attempt to cast doubt on the sales made by the Group to it. It premised its conclusion on the following:

- BWL China and the Primary Export Agent listed the same contact number on the packaging of skincare products;
- online job postings by the Primary Import Agent describing itself as "a branch of Best World Singapore", "a predecessor of BWL China's Hunan Branch" and "a Sinoforeign joint venture primarily engaged in international trade, import & export of cosmetics and dietary supplements, and that its parent company was listed on the main board of a foreign stock exchange";
- the Primary Import Agent's previous registered address displayed Best World signage and had a layout that appeared to facilitate product demonstration and showcases; and
- the misleading link between the Primary Import Agent's accumulated profits with the trademark royalty fees paid to the Group by the Primary Import Agent.

Our Response:

Please refer to www.drs-secret.com/products#device for information on the Group's range of electronic beauty devices.

Please refer to www.miraglo.com.sg/about.html# for information on the Group's Miraglo microfibre exfoliation products.

(a) The Primary Import Agent is an independent third party

The Report presents no evidence to establish any link between the Primary Import Agent and the Company, the Directors, the substantial shareholder of the Company or their associates.

The Company confirms that the Primary Import Agent, a company incorporated in China, is independent and not related to the Group. None of the Group, the Directors, the substantial shareholders of the Company or their associates have had any direct or indirect shareholding interests, directorship or management role in the Primary Import Agent.

As part of the initial scope of the Review, PwC will review the independence of the Primary Import Agent.

(b) The Group's sales and profits have increased since the transition to the Franchise Model

Bonitas claims that the Company's management secretly controlled and created the Primary Import Agent in order to fabricate sales and fraudulently overstate the Group's profits in FY2017.

However, since the Group's transition to the Franchise Model in June 2018 and the replacement of the Primary Import Agent by BWL China, the Group's sales and profits have increased substantially, as shown in the Company's announcement of the Group's unaudited financial statements for 3Q2018¹⁹ and 4Q2018²⁰.

The fact that the Company's sales and profits have increased substantially since the replacement of the Primary Import Agent disproves Bonitas' claim that the Primary Import Agent was created to fabricate sales and inflate profits.

Furthermore, based on PwC's interim update as of 12 April 2019, the Board and the Audit Committee understand that PwC has not identified any matters that may have a material impact on the Group's unaudited financial statements for FY2018²¹.

(c) <u>Information on the Primary Import Agent</u>

The Group initially engaged the Primary Import Agent to assist with the importation of the Products to China. As the business relationship developed, the Group gradually increased its business dealings with the Primary Import Agent, as the Primary Import Agent proved itself as a reliable business partner with its reliable service, and its cooperation with the Group to promote the Products in China in order to create a market and increase demand for the Products in China. Please refer to the section entitled "Transition from Export Model to Franchise Model in China" of the Company's clarification announcement dated 23 February 2019 for further information on the cooperation between the Group and the Primary Import Agent.

Announced by the Company on 8 November 2018.

Announced by the Company on 26 February 2019.

Announced by the Company on 26 February 2019.

(d) Reasons for the same contact number

Upon termination of the Distribution Agreement, BWL China took over the phone number formerly used by the Primary Import Agent to ensure a seamless transition from the Export Model to the Franchise Model. The Primary Import Agent no longer uses the phone number listed on page 6 of the Report.

Accordingly, Bonitas' call to that phone number on 22 February 2019 would have been answered by the Group's employees.

(e) The Primary Import Agent's use of the Group's signage

The Primary Import Agent operated under its own trade name, but was permitted to use the Group's brand and trade marks to promote the Products in China under the terms of the Distribution Agreement and a trademark license agreement entered into between the Primary Import Agent and the Company (the "**Trademark License Agreement**"). The Company charged the Primary Import Agent royalties for the use of the Group's brand and trademarks.

(f) Trademark royalty fees

The Company charged the Primary Import Agent royalties for the use of its brand and trademarks, as the Products had achieved wider distribution in China. However, the payment of such royalties was subject to the approval of the Changsha Municipal Bureau of Commerce (长沙市商务局) ("Changsha BOC") and State Administration of Foreign Exchange (SAFE)²², in line with the laws of China relating to the payment of royalties to foreign entities.

The Primary Import Agent applied for the payment of royalties in 2018. Such approval was subject to the Changsha BOC's review of the Primary Import Agent's audited financial statements, the Trademark License Agreement (which provided for the payment of trademark royalty fees by the Primary Import Agent), and the payment of withholding taxes in respect of such royalties. Approval for the payment of such royalties was obtained on 15 August 2018.

In view of the impending transition to the Franchise Model and the termination of the Distribution Agreement, the Company and the Primary Import Agent agreed to the payment of S\$10.3 million (which was S\$8.4 million net of withholding tax) as the trademark royalty fees for the use of the Group's brand and trade marks in its promotion of the Products prior to the termination of the Distribution Agreement in 3Q2018.²³

As part of their audit of the Group's financial statements of the Group for FY2018, EY will review the basis of computation of the royalty income and trace to cash receipts in relation to these royalty income.

Please refer to **Annex C** for copies of documentation showing the approval by Changsha BOC of the trademark royalty fees.

Please refer to Section 8 of the Company's announcement dated 8 November 2018 of the Group's unaudited financial statements for 3Q2018.

The SAFE approval process is handled by the relevant bank in China. Transactions which are passed through are implied to have received SAFE approval.

(g) <u>Job postings by the Primary Import Agent</u>

The Company has never been involved in the operations of the Primary Import Agent, and was not consulted on the online job postings on the third party recruitment websites which are presented in the Report as evidence of the links between the Primary Import Agent and the Company. Notwithstanding that the Report provides no evidence that the information on third party recruitment websites referenced in the Report were provided by the Primary Import Agent, the Company has informed the Primary Import Agent that it should not present itself as being part of the Group.

(h) No activity at the offices of the Primary Import Agent

The Primary Import Agent's registered address is at 长沙市开福区金泰路 199 号湘江世 纪城富湾国际 6 栋 1001 室. The Primary Import Agent has confirmed that it occupied Rooms 1001 and 1003 only. Room 1002 was never occupied by the Primary Import Agent.

The Company understands from the Primary Import Agent that with BWL China having taken over the distribution of the Products in China under the Franchise Model, the Primary Import Agent has downsized its operations and relocated its offices in 2019.

4. The Company does not conduct Direct Selling in China

Bonitas alleges that the Group is conducting direct selling of its skincare products in China without a valid licence.

Our Response:

(a) The Group's distribution strategies


The Company understands that growth in demand for its products requires an effective distribution strategy. Over the years, the Company has adopted various distribution strategies and tailored them to suit the markets in which the Group operates.

The Company takes its compliance obligations seriously, and developed the Franchise Model with advice from its professional advisors. The Company's legal counsel in China, Beijing Dacheng Law Offices, LLP (part of the global law firm Dentons), one of the largest law firms in China, has opined that the business of the Group under the Franchise Model complies with applicable laws and regulations. The Company will seek a separate legal opinion on whether its current distribution model in China constitutes direct selling under the applicable laws and regulations and will make further announcements to update shareholders in due course.

The Company recognises that laws and regulations, as well as the interpretation and application thereof, may change over time and/or in response to current developments. In order to ensure compliance and the security of its business and operations, the Company will continue to review the implementation of the Franchise Model, and will not hesitate to continue to fine tune and further develop the Franchise Model in order to remain effective and ensure compliance with applicable laws and regulations.

(b) Distribution under the Franchise Model

The chart below illustrates the distribution flow of the Products in China:



In the course of their business, Franchisees sell the Products to end consumers as well as other distributors in 3rd and 4th tier cities, also known as Province or City Representatives ("**Area Representatives**"), or sales representatives who promote the Products on behalf of Franchisees and Area Representatives ("**Sales Representatives**").

Franchisees and Area Representatives charge BWL China service fees on an hourly basis for providing market development services and training support to Sales Representatives.

Besides enjoying the price difference between the Franchisee price and the recommended retail price as a margin, Franchisees receive commissions from BWL China as a percentage of their monthly sales achieved. Sales Representatives also receive commissions from BWL China as a percentage of their monthly sales achieved.

The payment of commissions for sales is not a practice exclusive to direct selling distribution models. Many, if not most, sales models involve the payment of commissions for sales. The fact that commissions are paid for sales achieved does not mean that the Franchise Model constitutes direct selling or a violation of the Administrative Regulations on Commercial Franchise of China.

As part of their audit of the Group's financial statements of the Group for FY2018, EY will test the reasonableness of the commission expenses and the commission paid to Franchisees and Sales Representatives over a sample of selected transactions.

(c) <u>Commission structure under the Franchise Model</u>

The Report alleges that bonuses are paid to "Member Reps" (as described in the Report) in China for signing up new Member Reps based on a percentage of the new Member Rep's initial purchase.

The Company confirms that:

- (i) the Group did not pay any bonuses to Member Reps for recruitment of other Member Reps in China or any market in which the Group operates; and
- (ii) the commission structure presented on pages 21 and 23 of the Report is the commission structure applied in the Company's direct selling markets, such as Taiwan and Singapore (amongst others). This commission structure is not applied by the Group in China.

The Company does not permit member distributors from outside China to operate the Group's business in China.

(d) The Group is licenced to conduct the Franchise Model

As announced by the Company on 23 February 2019, the Group does not rely on the direct selling licence it received from Ministry of Commerce of the People's Republic of China ("MOFCOM") in June 2016 covering certain health supplement products over a limited geographical space in China (the "Direct Selling Licence") (See http://zxgl.mofcom.gov.cn/front/getEnterpriseInfo/330100400049586) ²⁴ for the Franchise Model or Manufacturing/Wholesale Model, or the Export Model previously employed in China.

While the Group was waiting to receive approval for the Direct Selling Licence, it simultaneously explored alternative strategies to evolve its business models in China, given the growth momentum it was experiencing at the time. Since obtaining the Direct Selling Licence in 2016, the Group has not conducted any sales in reliance on the Direct Selling Licence.

In 1Q2018, BWL China commenced the importation of the Products into China. In April 2018, the Group was notified by the MOFCOM that the Group was permitted to operate under the Franchise Model (see http://txjy.syggs.mofcom.gov.cn/manager/prosecute.do?method=add&id=6652565).

The Franchise Model officially commenced in June 2018, when Franchisees were required to purchase the Products directly from BWL China, instead of the third-party Import Agents. The Franchisees have since then continued to be independent third parties (in relation to the Group) and take ownership of the Products upon purchase.

(e) Alternative distribution models

The Company has received professional advice that the Group's business under the Franchise Model complies with applicable laws and regulations.

However, should there be any change in applicable laws and regulations or interpretation thereof which results in the Group's Franchise Model in China being found to require a direct selling licence, the Group will cooperate with the relevant authorities to expand the coverage of the Group's existing Direct Selling Licence and transition to a direct selling model in China accordingly.

Please also refer to the Company's announcement dated 1 July 2016 on the award of the Direct Selling Licence, as well as Section 10 of the Company's announcement dated 22 February 2017 of the Group's unaudited financial statements for FY2016 and page 6 of the Company's annual report for FY2016.

Prior to the transition to the Franchise Model, the Company had already explored the option of transitioning to a direct selling model in China. The Company believes that it will be able to do so if it becomes necessary without major disruptions to its operations in China.

Alternatively, the Group may also revert to the Export Model formerly adopted in China from 2014 to June 2018.

(e) Continued sales of the Products

Regardless of the distribution model adopted for the Products, the intellectual property rights and product registrations and licences in respect of the Products sold in China would remain valid. The Group has invested years to cultivate the market in China for the Products and believes that it would be able to continue to successfully sell the Products in China even under a different distribution model.

5. No Fraud

Bonitas alleges that the Founders engaged in a fraudulent scheme to profit from the Company based on:

- an overstatement of the dividends received by the Founders for FY2018, claiming that the Founders received S\$85 million in cash in the last three years;
- a change in accounting standards SFRS(I) 15 Revenue from Contracts with Customers, which resulted in certain expenses previously recorded in distribution costs as reductions to revenue;
- the quantum of EY's audit fees for FY2017 vis-à-vis audit fees for prior financial years; and
- the allegation that the Company failed to disclose that key manager positions in the Group's China skincare business were held by family members of Mdm. Hoan.

Our Response:

(a) Bonitas grossly overstated the Founders' dividend entitlements and suggested such dividend payments were made through increasing outstanding payments (i.e., trade and other payables)

The Company declared \$\$90.9 million of dividends from FY2010 to FY2018. The Report falsely alleges that the Founders received approximately \$\$74.4 million in dividends from FY2010 to FY2018. This would require the Founders to own 81.8% of the Company's shares from FY2010 to FY2018, which is plainly untrue.

The author of the Report has either miscalculated Founders' collective ownership of the Company, or deliberately misstated the amounts received by the Founders.

The Report falsely alleges that the Founders received approximately \$\$33.3 million in dividends for FY2018. Based on the Founders' combined shareholding interest as at 5 September 2018²⁵ and 4 December 2018²⁶ (the books closure dates for the interim dividends) and 46.7% as at the date of this announcement, the Founders are collectively entitled to S\$19.0 million in dividends for FY2018.

As explained in the Company's clarification announcement on the Group's unaudited financial statements for FY2018 dated 4 March 2019, trade and other payables increased from \$45.9 million as at 31 December 2017 to \$95.1 million as at 31 December 2018 mainly due to sales related expenses from the Franchise segment, higher accruals for commission and convention expenses. Such sales related expenses and commissions are usually settled on the following month. As at 31 March 2019, the Group's trade and other payables amounted to S\$79.2 million.²⁷

The Report has also drawn attention to the Group's receivables as at 31 December 2018 of S\$5.2 million. As disclosed in the Company's announcement of the Group's unaudited financial statements for FY201828, trade and other receivables decreased as at 31 December 2018 due to payments received from the Primary Import Agent. Under the Export Model, a large portion of the Group's sales comprised exports to the Import Agents in China, who were provided up to 120 day credit terms. Since the transition to the Franchise Model and the replacement of the Import Agents by BWL China, a large majority of the Company's sales are conducted on a cash payment before delivery basis, with credit terms provided only on a case by case basis. This has resulted in a reduction in the receivables of the Group.

(b) Dividends are paid to all shareholders

All shareholders of the Company are entitled to receive dividend payments based on the number of the Company's shares that they own. This is consistent with the Company's dividend policy to distribute at least 40% of the Company's annual profit after tax to shareholders in the form of dividends and/or bonus securities. The increase in the Founders' dividend payments simply corresponds to the increase in the Group's net profit after tax, and reflects the Company's growth.

(c) Consistent dividend payments

Since 2004, the Company has declared dividends totaling S\$115.3 million, notwithstanding that (i) the Group had total borrowings of only S\$1.4 million as at 31 March 2019²⁹; and (ii) the Company has not raised any funds from the equity capital markets since October 2005.

The allegation that the Company's sales were fabricated simply does not stand up to the facts, which is that the Company has consistently generated profits; profits which

²⁵ Please refer to the Company's announcement dated 7 August 2018 in relation to the notice of books closure for interim dividends.

²⁶ Please refer to the Company's announcement dated 8 November 2018 in relation to the notice of books closure for interim dividends.

Please refer to Section 8 of the Company's announcement dated 8 May 2019 for the Group's unaudited financial statements for 1Q2019.

²⁸ Announced by the Company on 26 February 2019.

²⁹ Please refer to Section 8 of the Company's announcement dated 8 May 2019 for the Group's unaudited financial statements for 1Q2019.

the Company has distributed to its shareholders over the years in line with good corporate governance.

(d) Change in independent auditor from FY2017

RSM had audited the financial statements of the Group, which included the results of the Group's Export Model from FY2014 to the end of FY2016. When RSM stepped down as the Company's external auditors in FY2017, RSM confirmed to the Company that they were not aware of any professional reasons why EY should not accept appointment as auditors of the Company. In a circular to shareholders dated 11 April 2017 in relation to the proposed change of auditors, the Company also confirmed that there were no disagreements between RSM and the Company on accounting treatments within the last 12 months.³⁰

(e) Non-audit fees

The fees paid to EY for non-audit services in FY2017 related to professional fees paid for potential projects of the Company. The Audit Committee reviewed the non-audit services provided by EY for FY2018 and is of the opinion that the provision of such non-audit services did not impair the independence or objectivity of EY as external auditors of the Company.

(f) Change in accounting standard had no impact on the Group's net profit after tax

Given that <u>all</u> SGX-ST-listed companies were required to adopt the SFRS(I) with effect from 1 January 2018, the allegation that the Company deliberately adopted SFRS(I) 15 (Revenue from Contracts with Customers) to make it more difficult to isolate the Group's China operations is absurd.

The application of SFRS(I) 15 resulted in the reclassification of S\$6,069,000 of expenses from distribution cost to be netted off against revenue in the Statement of Profit and Loss for FY2017.³¹ This reclassification had no impact on the Group's net profit after tax for FY2017 of approximately S\$55.1 million.³²

(g) <u>Disclosure of involvement of Mdm. Hoan's family members since 2012</u>

The Company has disclosed that Mr. Tang Boon Leong, Jansen ("Mr. Tang") and Ms. Tan Hui Keng, Phyllis ("Ms. Tan"), family members of Mdm. Hoan, are key employees of the Group on a yearly basis since 27 February 2012.³³

Please refer to Section 2 of the Company's circular to shareholders dated 11 April 2017 for the Company's reasons for the change of auditors from RSM to EY.

Please refer to Section 5 of the Company's announcement dated 26 February 2019 of the Group's unaudited financial statements for FY2018.

Please refer to Section 1(a)(i) of the Company's announcement dated 26 February 2018 of the Group's unaudited financial statements for FY2017 and Section 1(a)(i) of the Company's announcement dated 26 February 2019 of the Group's unaudited financial statements for FY2018.

Please refer to Section 18 of the Company's announcements dated 27 February 2012 of the Group's unaudited financial statements for FY2011, 26 February 2013 of the Group's unaudited financial statements for FY2012, 26 February 2014 of the Group's unaudited financial statements for FY2013 and 27 February 2015 of the Group's unaudited financial statements for FY2014, and Section 19 of the Company's announcements dated 25 February 2016 of the Group's unaudited financial statements for FY2015, 22 February 2017 of the Group's unaudited financial statements for FY2016, 26 February 2018

These disclosures were made in accordance to Rule 704(13) of the Mainboard Rules of the SGX-ST (the "**Listing Manual**"), which requires the disclosure of relatives of a director or chief executive officer or substantial shareholder who occupy *managerial* positions.

Mr. Tang and Ms. Tan are loyal employees of the Company who have been with the Company for about 14 years and 21 years, respectively. Both Mr. Tang and Ms. Tan joined the Group as rank and file employees who worked their way up the ranks to secure managerial positions in 2012. Accordingly, disclosure by the Company of the relationship between Mr. Tang, Ms. Tan and Mdm. Hoan were made in compliance with the Listing Manual.

The allegations made by Bonitas unfairly devalue the effort and commitment of Mr. Tang and Ms. Tan, and their contributions to the Group's success over the past decades.

Neither Mr. Tang nor Ms. Tan are part of the finance and accounting department of the Group. The Group has a formalized code of ethical conduct, as well as written policies on interested person transactions, conflicts of interest, non-trade transaction policies and whistle blowing. All of the Group's employees are required to read these policies, sign an agreement to comply with the code of ethical conduct, and are provided access to the policies through the Group's intranet.

The Company has also put in place a whistle-blowing framework endorsed by the Audit Committee where employees may, in confidence, raise concerns about possible corporate improprieties in matters of financial reporting or other matters to the independent Directors, and the independent Directors will ensure that arrangements are in place for the independent investigations of such matters. There have been no instances of whistle blowing concerning the allegations made in the Report.

6. No Fake Online Store Review Activity

Bonitas alleges that the Company artificially inflated its online store review count to overstate its online presence on sales channels in China.

Our Response:

(a) The Company does not distribute Products through Taobao.com or JD.com

The Company disclosed in its clarification announcement on 23 February 2019 that "[t]he Group does not directly conduct any sales transactions in China through online stores or social media, including Taobao."

Given that the Company does not distribute products on Taobao.com or JD.com, the allegation that the Company purchased fake reviews on Taobao.com and JD.com is misguided.

of the Group's unaudited financial statements for FY2017 and 26 February 2019 of the Group's unaudited financial statements for FY2018.

As "Youshangda" is not related to the Company, it makes even less sense that the Company would purchase fake reviews for the products touted by "Youshangda".

If there was in fact a sudden influx of reviews on the Group's products on Taobao.com and JD.com after the publication of the Article, it may well be that the Article simply raised awareness of the Group and its products. The Company has not taken any steps to encourage reviews on Taobao.com or JD.com.

Shareholders who wish to learn more about the Company's digital marketing strategy in China should refer to www.bestworld.com.sg/ir-investor-relations.html for further information.

(b) Purported "evidence" presented by Bonitas

While the Company notes that the reviews in the screenshots on pages 18 and 19 of the Report appear to be repeated, which suggests an artificial inflation of review count, reviews can be posted by anyone publicly. There is also no assurance that the images, as presented in the Report, are genuine.

The Company confirms that no reviews or searches conducted on "JD.com" or "Taobao.com" were purchased by or on behalf of the Company, its Directors or its employees.

7. Sales not limited to BWL Lifestyle Centers

Bonitas sought to cast doubt on the credibility of the financial performance of the Group's Franchise Model on the premise that it observed minimal sales transacted at BWL Lifestyle Centers.

Our Response:

(a) Purpose of BWL Lifestyle Centers

In the age of the digital economy, declining retail footfall is a phenomenon observed in many markets, and is not limited to China. With this in mind, the Company developed its digital marketing strategy specifically for the China market, which leverages on the widespread mobile internet usage in China to engage consumers through platforms like WeChat, Red and Weibo.

The BWL Lifestyle Centers in China are not intended by the Group to operate solely as retail stores, and primarily operate as physical locations for marketing events, outlets for consumers to visit for consultations and learn about the Products, or as pick up locations for Products in the event customers opt for self-pickup as opposed to delivery by courier.

Potential customers are often introduced to the Products through Sales Representatives, who are trained by Franchisees and Area Representatives in marketing the Products. Accordingly, potential customers who visit BWL Lifestyle Centers are typically accompanied by Sales Representatives, who are expected to service customers during their visits, educate customers on the use of the Products, and provide post-purchase support to customers.

It is extremely rare that a customer would visit a BWL Lifestyle Center without a Sales Representative as the cashiers or receptionists (who are not Sales Representatives) are not trained to service customers on the use of the Products.

(b) Purported Bonitas visits to Changsha Tianxin BWL Lifestyle Center

On page 12 of the Report, Bonitas claims that the Changsha Tianxin BWL Lifestyle Center was closed during business hours from the 20th to 22nd of March 2019.

This claim is incorrect as the Changsha Tianxin BWL Lifestyle Center was open on 20 March 2019. PwC has confirmed to the Company that its employees were at the Changsha Tianxin BWL Lifestyle Center on 20 March 2019 for an arranged visit as part of the Review.

Annex A

Ledger of Invoice Numbers

Sales to Changsha Best			
Invoice Listing for FY2017			
Posting Date No.	Currency Code	Amount	SGD
6/1/2017 SINV/BWI/0117/002	USD	633,741.20	917,534.95
6/1/2017 SINV/BWI/0117/003	USD	494,441.20	715,855.43
6/1/2017 SINV/BWI/0117/004	USD	170,600.20	246,996.16
6/2/2017 SINV/BWI/0217/001	USD	236,651.20	335,200.10
6/2/2017 SINV/BWI/0217/003	USD	1,600,916.30	2,267,587.48
6/2/2017 SINV/BWI/0217/006	USD	1,267,033.80	1,794,665.95
9/2/2017 SINV/BWI/0217/012	USD	858,713.40	1,216,308.28
13/2/2017 SINV/BWI/0217/007	USD	341,076.80	483,111.75
13/2/2017 SINV/BWI/0217/020	USD	208,709.50	295,622.61
15/2/2017 SINV/BWI/0217/021	USD	1,212,155.20	1,716,934.20
17/2/2017 SINV/BWI/0217/038 20/2/2017 SINV/BWI/0217/041	USD USD	2,105,458.40 932,358.40	2,982,236.55 1,320,621.34
20/2/2017 SINV/BWI/0217/044	USD	549,074.00	777,725.43
20/2/2017 SINV/BWI/0217/045	USD	493,994.40	699,708.98
21/2/2017 SINV/BWI/0217/063	USD	312,366.40	442,445.45
22/2/2017 SINV/BWI/0217/043	USD	91,286.80	129,301.45
22/2/2017 SINV/BWI/0217/047	USD	233,247.90	330,379.56
22/2/2017 SINV/BWI/0217/048	USD	308,726.60	437,289.93
22/2/2017 SINV/BWI/0217/064	USD	178,929.30	253,441.01
1/3/2017 SINV/BWI/0317/003	USD	190,332.60	266,871.24
3/3/2017 SINV/BWI/0317/004	USD	1,095,048.80	1,542,843.82
3/3/2017 SINV/BWI/0317/011	USD	1,095,048.80	1,535,401.87
13/3/2017 SINV/BWI/0317/027	USD	806,813.60	1,131,258.36
13/3/2017 SINV/BWI/0317/029	USD	179,673.60	251,925.92
13/3/2017 SINV/BWI/0317/030	USD	681,522.20	955,583.40
20/3/2017 SINV/BWI/0317/047	USD	479,350.80	672,112.62
22/3/2017 SINV/BWI/0317/046	USD	394,678.00	553,390.26
4/4/2017 SINV/BWI/0417/001	USD	2,212,006.50	3,091,984.71
6/4/2017 SINV/BWI/0417/003	USD	163,257.80	228,204.85
7/4/2017 SINV/BWI/0417/005	USD		
		693.00	968.69
7/4/2017 SINV/BWI/0417/028	USD	693.00	968.69
11/4/2017 SINV/BWI/0417/043	USD	693.00	968.69
11/4/2017 SINV/BWI/0417/047	USD	693.00	968.69
13/4/2017 SINV/BWI/0417/002	USD	313,459.20	438,159.23
13/4/2017 SINV/BWI/0417/009	USD	806,674.40	1,127,584.80
13/4/2017 SINV/BWI/0417/029	USD	881,809.00	1,232,609.37
13/4/2017 SINV/BWI/0417/031	USD	56,968.65	79,631.86
13/4/2017 SINV/BWI/0417/051	USD	693.00	968.69
13/4/2017 SINV/BWI/0417/055	USD	495.00	691.92
17/4/2017 SINV/BWI/0417/054	USD	12,293.30	17,183.81
19/4/2017 SINV/BWI/0417/030	USD	498,074.10	696,217.44
20/4/2017 SINV/BWI/0417/059	USD	99,497.40	139,079.36
24/4/2017 SINV/BWI/0417/064	USD	398,726.10	557,346.92
26/4/2017 SINV/BWI/0417/075	USD	41.20	57.59
3/5/2017 SINV/BWI/0517/002	USD	782,838.80	1,094,726.47
3/5/2017 SINV/BWI/0517/002		308,706.00	
	USD		431,696.32
5/5/2017 SINV/BWI/0517/032	USD	818,695.40	1,144,868.56
8/5/2017 SINV/BWI/0517/017	USD	648,714.60	907,166.39

Posting Date No.	Currency Code	Amount	SGD
12/5/2017 SINV/BWI/0517/026	USD	164,966.60	230,690.28
19/5/2017 SINV/BWI/0517/040	USD	745,001.20	1,041,814.15
22/5/2017 SINV/BWI/0517/082	USD	3,108.00	4,346.25
25/5/2017 SINV/BWI/0517/057	USD	79,250.90	110,824.93
26/5/2017 SINV/BWI/0517/056	USD	407,672.80	570,092.09
29/5/2017 SINV/BWI/0517/055	USD	1,498,880.40	2,096,043.34
2/6/2017 SINV/BWI/0617/003	SGD	356,500.00	356,500.00
5/6/2017 SINV/BWI/0617/005	SGD	820,653.35	820,653.35
7/6/2017 SINV/BWI/0617/002	SGD	210,350.00	210,350.00
7/6/2017 SINV/BWI/0617/006	SGD	1,289,535.85	1,289,535.85
9/6/2017 SINV/BWI/0617/008	SGD	712,224.60	712,224.60
15/6/2017 SINV/BWI/0617/023	SGD	1,260,706.85	1,260,706.85
19/6/2017 SINV/BWI/0617/031	SGD	356,979.75	356,979.75
19/6/2017 SINV/BWI/0617/032	SGD	356,500.00	356,500.00
20/6/2017 SINV/BWI/0617/025	SGD	2,104,724.00	2,104,724.00
22/6/2017 SINV/BWI/0617/046	SGD	669,056.00	669,056.00
22/6/2017 SINV/BWI/0617/047	SGD	1,737,398.75	1,737,398.75
22/6/2017 SINV/BWI/0617/048	SGD	121,353.00	121,353.00
22/6/2017 SINV/BWI/0617/048	SGD	69,320.00	69,320.00
3/7/2017 SINV/BWI/0717/001		751,077.80	
	SGD		751,077.80
3/7/2017 SINV/BWI/0717/004	SGD	1,387,252.20	1,387,252.20
6/7/2017 SINV/BWI/0717/003	SGD	1,670,444.00	1,670,444.00
6/7/2017 SINV/BWI/0717/009	SGD	224,075.00	224,075.00
6/7/2017 SINV/BWI/0717/010	SGD	684.00	684.00
11/7/2017 SINV/BWI/0717/006	SGD	749,880.00	749,880.00
11/7/2017 SINV/BWI/0717/007	SGD	581,259.35	581,259.35
14/7/2017 SINV/BWI/0717/028	SGD	25,614.40	25,614.40
17/7/2017 SINV/BWI/0717/015	SGD	355,502.50	355,502.50
19/7/2017 SINV/BWI/0717/043	SGD	969.00	969.00
25/7/2017 SINV/BWI/0717/044	SGD	969.00	969.00
26/7/2017 SINV/BWI/0717/049	SGD	969.00	969.00
28/7/2017 SINV/BWI/0717/047	SGD	197,174.00	197,174.00
31/7/2017 SINV/BWI/0717/050	SGD	945.00	945.00
2/8/2017 SINV/BWI/0817/006	SGD	969.00	969.00
4/8/2017 SINV/BWI/0817/003	SGD	113,396.30	113,396.30
4/8/2017 SINV/BWI/0817/010	SGD	969.00	969.00
8/8/2017 SINV/BWI/0817/009	SGD	91,328.10	91,328.10
10/8/2017 SINV/BWI/0817/017	SGD	969.00	969.00
14/8/2017 SINV/BWI/0817/019	SGD	699,084.90	699,084.90
16/8/2017 SINV/BWI/0817/030	SGD	144,466.20	144,466.20
18/8/2017 SINV/BWI/0817/032	SGD	409,505.50	409,505.50
21/8/2017 SINV/BWI/0817/037	SGD	2,272,965.10	2,272,965.10
21/8/2017 SINV/BWI/0817/044	SGD	340,344.00	340,344.00
22/8/2017 SINV/BWI/0817/035	SGD	683,378.70	683,378.70
22/8/2017 SINV/BWI/0817/058	SGD	969.00	969.00
23/8/2017 SINV/BWI/0817/090	SGD	0.00	-
28/8/2017 SINV/BWI/0817/060	SGD	1,033,577.00	1,033,577.00
28/8/2017 SINV/BWI/0817/067	SGD	969.00	969.00
30/8/2017 SINV/BWI/0817/066	SGD	169,385.00	169,385.00

Posting Date No.	Currency Code	Amount	SGD
4/9/2017 SINV/BWI/0917/024	SGD	969.00	969.00
7/9/2017 SINV/BWI/0917/005	SGD	363,493.75	363,493.75
7/9/2017 SINV/BWI/0917/033	SGD	969.00	969.00
8/9/2017 SINV/BWI/0917/020	SGD	2,773,339.60	2,773,339.60
12/9/2017 SINV/BWI/0917/051	SGD	969.00	969.00
14/9/2017 SINV/BWI/0917/046	SGD	149,175.00	149,175.00
14/9/2017 SINV/BWI/0917/047	SGD	913,100.15	913,100.15
15/9/2017 SINV/BWI/0917/061	SGD	969.00	969.00
18/9/2017 SINV/BWI/0917/055	SGD	359,350.00	359,350.00
18/9/2017 SINV/BWI/0917/056	SGD	114,624.40	114,624.40
20/9/2017 SINV/BWI/0917/062	SGD	986,442.70	986,442.70
20/9/2017 SINV/BWI/0917/063	SGD	1,123,424.45	1,123,424.45
21/9/2017 SINV/BWI/0917/075	SGD	969.00	969.00
25/9/2017 SINV/BWI/0917/076	SGD	2,668,801.80	2,668,801.80
26/9/2017 SINV/BWI/0917/077	SGD	1,496,867.85	1,496,867.85
27/9/2017 SINV/BWI/0917/079	SGD	2,186,470.00	2,186,470.00
2/10/2017 SINV/BWI/1017/004	SGD	969.00	969.00
5/10/2017 SINV/BWI/1017/008	SGD	1,037,319.00	1,037,319.00
5/10/2017 SINV/BWI/1017/014	SGD	969.00	969.00
9/10/2017 SINV/BWI/1017/013	SGD	1,115,180.65	1,115,180.65
10/10/2017 SINV/BWI/1017/015	SGD	185,603.00	185,603.00
12/10/2017 SINV/BWI/1017/021	SGD	1,767,940.70	1,767,940.70
12/10/2017 SINV/BWI/1017/022	SGD	191,410.00	191,410.00
12/10/2017 SINV/BWI/1017/028	SGD	969.00	969.00
16/10/2017 SINV/BWI/1017/031	SGD	1,884,114.10	1,884,114.10
19/10/2017 SINV/BWI/1017/033	SGD	93,731.00	93,731.00
19/10/2017 SINV/BWI/1017/046	SGD	969.00	969.00
20/10/2017 SINV/BWI/1017/047	SGD	738,709.35	738,709.35
23/10/2017 SINV/BWI/1017/052	SGD	969.00	969.00
26/10/2017 SINV/BWI/1017/051	SGD	694,208.70	694,208.70
26/10/2017 SINV/BWI/1017/054	SGD	1,867,303.70	1,867,303.70
27/10/2017 SINV/BWI/1017/058	SGD	392,176.50	392,176.50
1/11/2017 SINV/BWI/1117/016	SGD	969.00	969.00
2/11/2017 SINV/BWI/1117/004	SGD	1,658,462.85	1,658,462.85
2/11/2017 SINV/BWI/1117/015	SGD	55,462.20	55,462.20
3/11/2017 SINV/BWI/1117/005	SGD	1,635,856.00	1,635,856.00
7/11/2017 SINV/BWI/1117/024	SGD	1,221,541.70	1,221,541.70
8/11/2017 SINV/BWI/1117/022	SGD	744,204.85	744,204.85
8/11/2017 SINV/BWI/1117/031	SGD	969.00	969.00
10/11/2017 SINV/BWI/1117/032	SGD	134,297.50	134,297.50
10/11/2017 SINV/BWI/1117/033	SGD	983,600.20	983,600.20
15/11/2017 SINV/BWI/1117/040	SGD	2,641,290.00	2,641,290.00
17/11/2017 SINV/BWI/1117/050	SGD	1,696,963.30	1,696,963.30
17/11/2017 SINV/BWI/1117/066	SGD	1,188,186.75	1,188,186.75
20/11/2017 SINV/BWI/1117/072	SGD	969.00	969.00
20/11/2017 SINV/BWI/1117/073	SGD	969.00	969.00
20/11/2017 SINV/BWI/1117/074	SGD	969.00	969.00
20/11/2017 SINV/BWI/1117/075	SGD	969.00	969.00
22/11/2017 SINV/BWI/1117/070	SGD	1,987,533.30	1,987,533.30

Posting Date No.	Currency Code	Amount	SGD
23/11/2017 SINV/BWI/1117/081	SGD	126,560.00	126,560.00
24/11/2017 SINV/BWI/1117/090	SGD	8.50	8.50
27/11/2017 SINV/BWI/1117/089	SGD	1,370,141.15	1,370,141.15
27/11/2017 SINV/BWI/1117/103	SGD	12.50	12.50
6/12/2017 SINV/BWI/1217/001	SGD	996,852.35	996,852.35
7/12/2017 SINV/BWI/1217/017	SGD	356,005.00	356,005.00
11/12/2017 SINV/BWI/1217/014	SGD	1,594,291.85	1,594,291.85
12/12/2017 SINV/BWI/1217/034	SGD	371,847.50	371,847.50
13/12/2017 SINV/BWI/1217/039	SGD	12.50	12.50
14/12/2017 SINV/BWI/1217/028	SGD	434,389.20	434,389.20
15/12/2017 SINV/BWI/1217/038	SGD	393,447.75	393,447.75
19/12/2017 SINV/BWI/1217/044	SGD	404,650.00	404,650.00
19/12/2017 SINV/BWI/1217/048	SGD	285,763.60	285,763.60
20/12/2017 SINV/BWI/1217/036	SGD	2,594,378.40	2,594,378.40
20/12/2017 SINV/BWI/1217/040	SGD	1,320,646.00	1,320,646.00
20/12/2017 SINV/BWI/1217/049	SGD	826,885.00	826,885.00
21/12/2017 SINV/BWI/1217/051	SGD	969.00	969.00
21/12/2017 SINV/BWI/1217/052	SGD	969.00	969.00
22/12/2017 SINV/BWI/1217/056	SGD	969.00	969.00
22/12/2017 SINV/BWI/1217/057	SGD	969.00	969.00
22/12/2017 SINV/BWI/1217/058	SGD	969.00	969.00
22/12/2017 SINV/BWI/1217/059	SGD	969.00	969.00
22/12/2017 SINV/BWI/1217/060	SGD	969.00	969.00
22/12/2017 SINV/BWI/1217/061	SGD	969.00	969.00
22/12/2017 SINV/BWI/1217/062	SGD	969.00	969.00
22/12/2017 SINV/BWI/1217/063	SGD	969.00	969.00
22/12/2017 SINV/BWI/1217/064	SGD	969.00	969.00
22/12/2017 SINV/BWI/1217/065	SGD	798.00	798.00
T . 10 1			100 645 646 71
Total Sales in SGD			109,645,648.74
Less: Credit Notes Less: Product rebate		-	1,663,905.00
Total Net Sales for 01 Ja	an 17 to 31 Dec 17	-	2,200,000.00
Total Net Sales 101 01 3	III I / (O DI DEC I/		103,701,743.74

Credit Note Listing

Credit Note Listing									
Posting Date ,	Sell-to Customer No.	Customer Name	Bill-to Customer No.		Currency Code			SGD	Amount Including GST
9/1/2017 SPCM/BWI/0117/003	AR0025	CHANGSHA BAI SHI	TI AR0025	CHANGSHA BAI SHI TE WEI COMPANY, LIMITED	USD	9/1/2017	5,100.00	7,280.00	5,100.00
1/3/2017 SPCM/BWI/0317/006	AR0025	CHANGSHA BAI SHI	TI AR0025	CHANGSHA BAI SHI TE WEI COMPANY, LIMITED	USD	1/3/2017	49.20	69.26	49.20
1/3/2017 SPCM/BWI/0317/008	AR0025	CHANGSHA BAI SHI	TI AR0025	CHANGSHA BAI SHI TE WEI COMPANY, LIMITED	USD	1/3/2017	112.00	151.02	112.00
1/3/2017 SPCM/BWI/0317/009	AR0025	CHANGSHA BAI SHI	TI AR0025	CHANGSHA BAI SHI TE WEI COMPANY, LIMITED	USD	1/3/2017	122.30	168.67	122.30
1/3/2017 SPCM/BWI/0317/010	AR0025	CHANGSHA BAI SHI	TI AR0025	CHANGSHA BAI SHI TE WEI COMPANY, LIMITED	USD	1/3/2017	65.40	88.19	65.40
1/3/2017 SPCM/BWI/0317/011	AR0025	CHANGSHA BAI SHI	TI AR0025	CHANGSHA BAI SHI TE WEI COMPANY, LIMITED	USD	1/3/2017	12.30	17.13	12.30
1/3/2017 SPCM/BWI/0317/012	AR0025	CHANGSHA BAI SHI	TI AR0025	CHANGSHA BAI SHI TE WEI COMPANY, LIMITED	USD	1/3/2017	16.40	22.36	16.40
1/3/2017 SPCM/BWI/0317/013	AR0025	CHANGSHA BAI SHI	TI AR0025	CHANGSHA BAI SHI TE WEI COMPANY, LIMITED	USD	1/3/2017	23.90	33.28	23.90
3/3/2017 SPCM/BWI/0317/027	AR0025	CHANGSHA BAI SHI	TI AR0025	CHANGSHA BAI SHI TE WEI COMPANY, LIMITED	USD	2/4/2017	1,095,048.80	1,542,843.82	1,095,048.80
10/3/2017 SPCM/BWI/0317/007	AR0025	CHANGSHA BAI SHI	TI AR0025	CHANGSHA BAI SHI TE WEI COMPANY, LIMITED	USD	10/3/2017	32.80	44.00	32.80
22/3/2017 SPCM/BWI/0317/029	AR0025	CHANGSHA BAI SHI	TI AR0025	CHANGSHA BAI SHI TE WEI COMPANY, LIMITED	USD	22/3/2017	32.80	44.23	32.80
22/3/2017 SPCM/BWI/0317/030	AR0025	CHANGSHA BAI SHI	TI AR0025	CHANGSHA BAI SHI TE WEI COMPANY, LIMITED	USD	22/3/2017	73.70	105.20	73.70
22/3/2017 SPCM/BWI/0317/031	AR0025	CHANGSHA BAI SHI	TI AR0025	CHANGSHA BAI SHI TE WEI COMPANY, LIMITED	USD	22/3/2017	20.60	28.09	20.60
29/3/2017 SPCM/BWI/0317/028	AR0025	CHANGSHA BAI SHI	TI AR0025	CHANGSHA BAI SHI TE WEI COMPANY, LIMITED	USD	29/3/2017	32.80	45.24	32.80
1/6/2017 SPCM/BWI/0617/001	AR0025	CHANGSHA BAI SHI	TI AR0025	CHANGSHA BAI SHI TE WEI COMPANY, LIMITED	USD	1/6/2017	127.65	176.68	127.65
1/6/2017 SPCM/BWI/0617/002	AR0025	CHANGSHA BAI SHI	TI AR0025	CHANGSHA BAI SHI TE WEI COMPANY, LIMITED	USD	1/6/2017	109.75	151.90	109.75
15/6/2017 SPCM/BWI/0617/007	AR0025	CHANGSHA BAI SHI	TI AR0025	CHANGSHA BAI SHI TE WEI COMPANY, LIMITED	USD	15/6/2017	34.60	47.89	34.60
21/6/2017 SPCM/BWI/0617/009	AR0025	CHANGSHA BAI SHI	TI AR0025	CHANGSHA BAI SHI TE WEI COMPANY, LIMITED	USD	21/6/2017	15,754.80	21,805.95	15,754.80
1/8/2017 SPCM/BWI/0817/009	AR0025	CHANGSHA BAI SHI	TI AR0025	CHANGSHA BAI SHI TE WEI COMPANY, LIMITED	USD	1/8/2017	162.00	219.81	162.00
1/8/2017 SPCM/BWI/0817/010	AR0025	CHANGSHA BAI SHI	TI AR0025	CHANGSHA BAI SHI TE WEI COMPANY, LIMITED	USD	1/8/2017	218.60	296.61	218.60
1/8/2017 SPCM/BWI/0817/011	AR0025	CHANGSHA BAI SHI	TI AR0025	CHANGSHA BAI SHI TE WEI COMPANY, LIMITED	USD	1/8/2017	92.55	125.58	92.55
22/8/2017 SPCM/BWI/0817/004	AR0025	CHANGSHA BAI SHI	TI AR0025	CHANGSHA BAI SHI TE WEI COMPANY, LIMITED	SGD	22/8/2017	567.00	567.00	567.00
11/9/2017 SPCM/BWI/0917/005	AR0025	CHANGSHA BAI SHI	TI AR0025	CHANGSHA BAI SHI TE WEI COMPANY, LIMITED	USD	11/9/2017	203.90	276.93	203.90
12/9/2017 SPCM/BWI/0917/006	AR0025	CHANGSHA BAI SHI	TI AR0025	CHANGSHA BAI SHI TE WEI COMPANY, LIMITED	USD	12/9/2017	306.90	416.81	306.90
4/10/2017 SPCM/BWI/1017/002	AR0025	CHANGSHA BAI SHI	TI AR0025	CHANGSHA BAI SHI TE WEI COMPANY, LIMITED	USD	4/10/2017	392.40	532.93	392.40
10/10/2017 SPCM/BWI/1017/004	AR0025	CHANGSHA BAI SHI	TI AR0025	CHANGSHA BAI SHI TE WEI COMPANY, LIMITED	USD	10/10/2017	61,388.00	83,373.62	61,388.00
20/11/2017 SPCM/BWI/1117/004	AR0025	CHANGSHA BAI SHI	TI AR0025	CHANGSHA BAI SHI TE WEI COMPANY, LIMITED	USD	20/11/2017	95.50	130.07	95.50
21/11/2017 SPCM/BWI/1117/002	AR0025	CHANGSHA BAI SHI	TI AR0025	CHANGSHA BAI SHI TE WEI COMPANY, LIMITED	USD	21/11/2017	2,838.00	3,865.43	2,838.00
21/11/2017 SPCM/BWI/1117/003	AR0025	CHANGSHA BAI SHI	TI AR0025	CHANGSHA BAI SHI TE WEI COMPANY, LIMITED	SGD	21/11/2017	388.60	388.60	388.60
24/11/2017 SPCM/BWI/1117/005	AR0025	CHANGSHA BAI SHI	TI AR0025	CHANGSHA BAI SHI TE WEI COMPANY, LIMITED	SGD	24/11/2017	56.85	56.85	56.85
1/12/2017 SPCM/BWI/1217/001	AR0025	CHANGSHA BAI SHI	TI AR0025	CHANGSHA BAI SHI TE WEI COMPANY, LIMITED	SGD	1/12/2017	24.00	24.00	24.00
19/12/2017 SPCM/BWI/1217/006	AR0025	CHANGSHA BAI SHI	TI AR0025	CHANGSHA BAI SHI TE WEI COMPANY, LIMITED	USD	19/12/2017	309.55	417.42	309.55
20/12/2017 SPCM/BWI/1217/010	AR0025	CHANGSHA BAI SHI	TI AR0025	CHANGSHA BAI SHI TE WEI COMPANY, LIMITED	SGD	20/12/2017	48.90	48.90	48.90
20/12/2017 SPCM/BWI/1217/011	AR0025	CHANGSHA BAI SHI	TI AR0025	CHANGSHA BAI SHI TE WEI COMPANY, LIMITED	USD	20/12/2017	30.80	41.53	30.80

Total sales CN listing 1,663,905.00

Annex B

Sample of Invoices and Export Documentation

CHANGSHA BAI SHI TE WEI COMPANY, LIMITED 1001, BUILDING 6, FUWAN INTERNATIONAL, XIANGJIANG CENTURY TOWN, KAIFU DISTRICT, CHINA 413005

Shipped To:

CHANGSHA BAI SHI TE WEI COMPANY, LIMITED 1001, BUILDING 6, FUWAN INTERNATIONAL, XIANGJIANG CENTURY TOWN, KAIFU DISTRICT, CHINA 413005

Tax Invoice

No. SINV/BWI/1117/040

GST Reg. No. M2-0097040-3

Page 1

Bill-to Customer No. AR0025
Posting Date 15/11/17
Due Date 15/12/17

Payment Terms

Ext. Doc. No. SUINV/BWI/1117/040

NO.	DESCRIPTION	GST	AMOUNT
	Shipment No. SSHP/BWI/1117/187: Order Ref. No.: CNPO1706001	2	
8887723280184	DR SEC SKIN SHIELD MATT BOTTL	GST0	316,032.00
	Lot No. L10686C Expiration Date 23/03/20		
	Shipment No. SSHP/BWI/1117/188: Order Ref. No.: CNPO1710000	3	
8887723280184	DR SEC SKIN SHIELD MATT BOTTL	GST0	97,728.00
	Lot No. L10686C Expiration Date 23/03/20		
8887723280047	DR'S SECRET MOISTURIZER BOTTL	GST0	268,851.60
	Lot No. 11000 Expiration Date 31/07/20		
	Shipment No. SSHP/BWI/1117/189: Order Ref. No.: CNPO1707000	4	
8887723280443	DR'S SECRET SKIN RECON T4 BOTTL	GST0	1,183,700.00
	Lot No. 7052303/2 Expiration Date 23/05/20		
	Lot No. 7052303/3 Expiration Date 23/05/20		
	Lot No. 7052303/4 Expiration Date 23/05/20		
	Lot No. 7052303/5 Expiration Date 23/05/20		
	Lot No. 7052303/6 Expiration Date 23/05/20		
	Lot No. 7052303/7 Expiration Date 23/05/20		
	Lot No. 7052303/8 Expiration Date 23/05/20		
	Lot No. 7052303/9 Expiration Date 23/05/20		
	Lot No. 7052303/10 Expiration Date 23/05/20		
8887723280047	DR'S SECRET MOISTURIZER BOTTL	GST0	774,428.40
	Lot No. 11000 Expiration Date 31/07/20		
	Shipment No. SSHP/BWI/1117/190: Order Ref. No.: SUINV/BWI/11	17/040	
L0051	PALLET PCS	GST0	550.00
	Total SGD		2,641,290.00

Any disagreement with the contents of this Tax Invoice must be notified in writing within 7 days from the date of issue
This is a computer generated invoice No signature is required

CHANGSHA BAI SHI TE WEI COMPANY, LIMITED 1001, BUILDING 6, FUWAN INTERNATIONAL, XIANGJIANG CENTURY TOWN, KAIFU DISTRICT, CHINA 413005

Shipped To:

CHANGSHA BAI SHI TE WEI COMPANY, LIMITED 1001, BUILDING 6, FUWAN INTERNATIONAL, XIANGJIANG CENTURY TOWN, KAIFU DISTRICT, CHINA 413005

Tax Invoice

No. SINV/BWI/1117/040

GST Reg. No. M2-0097040-3

Page 2

Bill-to Customer No. AR0025 Posting Date 15/11/17 Due Date 15/12/17

Payment Terms

Ext. Doc. No. SUINV/BWI/1117/040

NO. DESCRIPTION GST AMOUNT

GST Identifier	GST %	Tax Based Amount	GST Amount	Total Amount
GST0	0	2,641,290.00	0.00	2,641,290.00

Dimerco Express Singapore Pte. Ltd.

80 MARINE PARADE ROAD, #10-02 PARKWAY PARADE, SINGAPORE, 449269 SINGAPORE

TEL:6542-2233 FAX:6542-3442

BILL OF LADING

Shipper				B/L Nu	ımber		S/O Number	
BEST WORLD INTERI 26 TAI SENG STREET		LTD		DFS02	23015061		DIMSINO17110	000045
SINGAPORE 534057				Evnort	References	,		
				Export	Kererences			
Consignee CHANGSHA BAI SHI TE 1001, BUILDING 6, FUWA XIANGJIANG CENTURY KAIFU DISTRICT, HONG KONG	AN INTERNA							
Notify Party GUANGZHOU KUAIJIE	CUSTOMS CL	EARANCE	& INSPECTION		f Origin APORE			
CLEARANCE CO.,LTD	000101010		a mor Edition	Also N	otify Party	-Routing & Instruc	tions	
Pre-Carriage By		Place of R SINGAPO						
Vessel WAN HAI 301		Voyage N212						
Port of Loading SINGAPORE				Type of CY/C	f Movemer	nt		
Marks and Numbers Container and Seal Nos.	No. of P	kgs	Description of Package and Goods			ods	Gross Weight	Measurement
IAAE029871/40HQ CHANGSHA BAI SHI TE WEI COMPANY LTD INV			DR'S SECRET SK SHIELD MATTE, INV NO# SUINV/ FREIGHT PREPA SHIPPER'S LOAL	1 X 40'HC CONTAINER SAID TO CONTAIN: DR'S SECRET SKIN RECON, DR'S SECRET SKIN SHIELD MATTE, DR'S SECRET MOISTURIZER INV NO# SUINV/BWI/1117/040 FREIGHT PREPAID SHIPPER'S LOAD, COUNT AND SEAL CY TO CY 1X40HQ			7055.000 KGS	
Total Number of Container	Total: 22	in words)	0				Total: 7055	Total: 29.405
SAY TOTAL ONE FOR	RTY FOOT H	HIGH CUE	BE CONTAINERS (ONLY			T	
Tariff Item#			Charge				Prepaid	Collect
						Total:		
Shipper declared value \$,	subje	ect to extra freig	ht as per ta	riff and carriers lial	bility limits	
The Carrier hereby acknow				Freight Payabl	le At		Date Laden On Boa 2017-11-15	rd
packages or other shipping above in apparent external	good order and	d condition u	unless otherwise	No of Original	l B/L		Place and Date of Is	sue
stated for the above carriag and every person having an	n interest in the	Goods is a	dvised that the	0			SINGAPORE 201	17-11-15
receipt, custody, carriage, a terms and conditions set for and the reverse hereof, who	orth and incorpo	orated by ref	ference on this side	Dimerco Exp	ress Singa	pore Pte. Ltd.As t	he Carrier	
by the Carrier, one origina duly endorsed in exchange original Bill of Lading has of which being accomplish	l of this Bill of for the Goods. been signed in	Lading mus In witness the number	st be surrendered whereof the					



DIMERCO EXPRESS GROUP

TERMS AND CONDITIONS

DEPORTION:

"Until make the instancial Ocean Marcal assented on the finat hamsefuld may workshould, highest or other means of compresses which is extabll to reductioned in which a crity party that Carrier and also includes any other threads and which Greeds may be included for the purpose of being many parts of the standard of the carrier and does include a carrier threads. If the carrier are for small a principal and the carrier and the final and the carrier and the carrier and the carrier and the many that had been a final fill adding a sort and the carrier and the carrier and the final and the carrier and the ca

described by ear in behalf of the Manchat mission of the comparison of the compariso

A CARDITATE OF CONTINUATE MERCHANGE OF THE ADMINISTRATION OF THE ADMINISTRATE BE UN1500 PER BECKERGE FOR CUSTICINALLY REPLEITED US.

4. CARDITATE SETSOD SIBILITY

5. A PORT TO PORT SIMPLETE. Except to other winds provided bearing the Carrier's nepositivity \$\frac{1}{2}\$ colds of hall commance of the time what winds by the Carrier's nepositivity \$\frac{1}{2}\$ for the Carrier's nepositivity \$\frac{1}{2}\$ for the Carrier's new hall commance of the time what winds by the Carrier's new hall of the Carrier's new hall of the Carrier's new hall new hall of the Carrier's new hall of the Carrier's new hall new hall of the Carrier's new hall n

D. AD VALOREM INCLASED VALUE OF PACKAGES OR SEMPRING UNIT.

In Carmir's labely may be increased to higher which by a declaration in uniting of the whole of the Goods by the Manchast upon believey to the Carmir's of the Goods for I signature. Such higher which we have been as the first of the Did I following in the precess provided for each disregard by the Carmir, exten finight post in real-core. If the actual cubes of the Goods of the Goods of the Carmir's thoughty from a real-core of the declared which and any partial laws or change shall be only to the provided of the Carmir's thoughty from the provided of the Carmir's thoughty from the Carmir's thoughty from the lower of the Goods of the Carmir's thoughty from the Carmir's thoughty from the label of the Carmir's thoughty from the label of the Carmir's thought of the date of the Carmir's thought of the Carmir's continue of the Carmir's th

only making and the same of extramination of man. Including a copy like a collision has been seen to be a first a collision of forms of hours of the Good and a collision of the same of the Good and the Good

this dis continues as delined by Centric with the stab inner.

In Mondanie hall default dischain dismontries all hall beautify all hall be active to continue to the surprised by the mentional property of the Greek's articular property in a continue to the surprised by an an admittant property of the Greek's articular property of the surprised by a continue to the surprised by the Centric markets in the decided by a continue to the surprised by a continue to

The state of the s

communes, may winter us not be manufact actors; a change of the Goods and place the pool, or any performant of Camine's disposal at any place which the Goods and place the pool, or any performant of Camine's disposal at any place which the Gomine hall down and and communes these pools are no probably of the Camine insepect of "arkiforeds' hall coate; or all communes are not to be a commune that the pools are the pools of the pools of collections; and appropriate the communes are not communes and the communes are not considered from the community of the communes are not considered from the community of the comm

comparation for extra cert in welling from the circums bases randomed to alway.

(i) If their wangs, discharge, are expressed when always a distinct makes amangament to show analyst forward the goods, it is a good that he shall do so only as a good for all a strain and a strain

G. Integration of Greekt: Uppaceway, the Carrier stray present entherized by the Carrier shall be suitfied, but under no obligation, to open east integer the Greekt in any Cardinates or pushing a tray time.

1. GO VERTRICATENT DIRECTIONS, ETC.: The Cennics Micror and Versal shall have bloomy to comply with any orders or a backing department, arrival, arrival, notes, period of Carrier (in page as, decidence, destination, administratory or entheriors, be necessary ground up the parameter of any action or a department of many actions or a surface and parameters of the present having of early pages. The action of the complete of the Carrier in negacity of the Carrier in ne

case. Inaddition to all other liberties bassin the Carrier shall have the right to withhold delivery of making to, deposit or discharge the good of any place what source, runnables of the year of the good or partial imposed upon or extracted from the causins by any proximant or depositions and appearance in the case of the good or partial imposed upon or extracted from the causins by any proximant or depositions of the above circumstance, the Goods shall be applyed to the case of the cause of the above circumstance, the Goods shall be upon the case of the cause of the above circumstance, the Goods shall be applyed by the case of water or consigner and shall be intended to

he really a rither in it and expense and all expenses and charges in increased leading to great the property of the real and the property of the property of the real and the property of the

from the several with each mixet; the Curiax (ability at the labels for any law or elements to exceed by the Curiax's applicate.

Manchaer (abil defined, minimity and hald harmless the Curiax appliest any laws or damage to the several or carge or to any persons or property cawed by infinitumable, applies or elements or produced to the contract of their maters, whether cuch Manchaer to principal are applied and sufficiently to these was evaluated as described as a general and the contract of their maters, whether cuch Manchaer to principal are applied and sufficiently to the security of the particular applied as a produced or any time without or appearation.

WARLFARTY Manchaer warmant that he appearing the the time harms described as a cargo course or for the contract in the Goods or any persons who has a present or fortun interest in the Goods.

IFFERIGHT AND CHARGES:

information, explorates or desposed specific the strangestime product of the content of their nature, whether with discolard be principle or spired and run. 16-66 or shipped many in the WERLANT, Manihaut washed that appears have the transparent of the formation of the content of the content

He west company to overse to consider the same of the same outputs of the same of the same of the same outputs of the same out

pared!
I s.F.V.F.R.BILITY: If cay previses in this Bill of Leding is half to be incalled or
manifementally by any courter in pulse by or self-rapidately, agany to thely run himshifty or manifementally, shall estand early to each participate, the weblinty of the
manifemental by any courter in pulse by or self-rapidately of pulse of the control of the self-rapidately or the pulse of the control of the self-rapidately or the pulse of the control of the self-rapidately or the pulse of the control of the self-rapidately or the pulse of the control of the self-rapidately or the pulse of the control of the self-rapidately or the pulse of the control of the self-rapidately or the self-rap

manising provision (All are by difficiel density, and the Bill of Leiding contact) hall be caused on a year amount or unanomerous provision has been been as the second of the second of

bestworld

PACKING LIST

Date


13-11-17

Invoice No.

SUINV/BWI/1117/040

Packing Order No.

PK/BWI/1117/016



_											
Ca	rton	No.	Description			Lot No. /	Expiry Date	Net Weight	Gross Weight	Carton Dimension	PO Reference
1	-	40	DR'S SECRET SKIN RECON	30ml	美肤霜	7052303/2	23-05-2020	269.10		37 x 37 x 15	CNPO17070004
41	-	80	DR'S SECRET SKIN RECON	30ml	美肤霜	7052303/3	23-05-2020	3.24 269.10	357.00	37 x 37 x 15	CNPO17070004
81	-	120	DR'S SECRET SKIN RECON	30ml	美肤霜	7052303/4	23-05-2020	1.38 269.10	356.00	37 x 37 x 15	CNPO17070004
121	-	160	DR'S SECRET SKIN RECON	30ml	美肤霜	7052303/5	23-05-2020	0.90 269.10	355.00	37 x 37 x 15	CNPO17070004
161	-	200	DR'S SECRET SKIN RECON	30ml	美肤霜	7052303/6	23-05-2020	0.48 269.10		37 x 37 x 15	CNPO17070004
201	-	240	DR'S SECRET SKIN RECON	30ml	美肤霜	7052303/7	23-05-2020	0.35 269.10		37 x 37 x 15	CNPO17070004
241	-	280	DR'S SECRET SKIN RECON	30ml	美肤霜	7052303/8	23-05-2020	2.76 269.10	340.00	37 x 37 x 15	CNPO17070004
281	-	320	DR'S SECRET SKIN RECON	30ml	美肤霜	7052303/9	23-05-2020	4.76 269.10		36 x 36 x 19	CNPO17040004
321	-	338	DR'S SECRET SKIN RECON	30ml	美肤霜	7052303/10	23-05-2020	4.83 117.30	341.00	36 x 36 x 19	CNPO17040004
339		386	DR'S SECRET SKIN SHIELD MATTE	30ml	呵护霜(清爽型)	L10686C	23-03-2020	5.45 192.00	287.00	36 x 36 x 19	CNPO17060012
387	-	434	DR'S SECRET SKIN SHIELD MATTE	30ml	呵护霜 (清爽型)	L10686C	23-03-2020	192.00	287.00	36 x 36 x 19	CNPO17060012
435	-	482	DR'S SECRET SKIN SHIELD MATTE	30ml	呵护霜 (清爽型)	L10686C	23-03-2020	142.72	287.00	36 x 36 x 19	CNPO17100003
483	-	511	DR'S SECRET SKIN SHIELD MATTE	30ml	呵护霜 (清爽型)	L10686C	23-03-2020	49.28 112.00	180.00	36 x 36 x 19	CNPO17100003
								1.60			
512	8	553	DR'S SECRET MOISTURIZER	30ml	润肤霜	11000	31-07-2020	189.00	317.00	36 x 36 x 19	CNPO17040004
554		595	DR'S SECRET MOISTURIZER	30ml	润肤霜	11000	31-07-2020	189.00	317.00	36 x 36 x 19	CNPO17040004
596	-	637	DR'S SECRET MOISTURIZER	30ml	润肤霜	11000	31-07-2020	189.00	317.00	36 x 36 x 19	CNPO17040004
638	8	679	DR'S SECRET MOISTURIZER	30ml	润肤霜	11000	31-07-2020	189.00	317.00	36 x 36 x 19	CNPO17040004
680	-	721	DR'S SECRET MOISTURIZER	30ml	润肤霜	11000	31-07-2020	189.00	317.00	36 x 36 x 19	CNPO17040004
722	3	763	DR'S SECRET MOISTURIZER	30ml	润肤霜	11000	31-07-2020	189.00	317.00	36 x 36 x 19	CNPO17040004
764	-	805	DR'S SECRET MOISTURIZER	30ml	润肤霜	11000	31-07-2020	128.66 60.35	317.00	36 x 36 x 19	CNPO17040004 CNPO17100003
806	E	847	DR'S SECRET MOISTURIZER	30ml	润肤霜	11000	31-07-2020	189.00	317.00	36 x 36 x 19	CNPO17100003
848		889	DR'S SECRET MOISTURIZER	30ml	润肤霜	11000	31-07-2020	189.00	317.00	36 x 36 x 19	CNPO17100003

No. of Pallets : Total no. of Cartons Total Weight (KG) :

Authorized Singure

M 153

Best World International Atd

22

889.00 7,055.00

Acknowledge Receipt By

4,684.85

Best World International Ltd

7,055.00

26 Tai Seng St #05-01 Singapore 534057 Tel (65) 6899 0088 Fax (65) 6636 1531 www.bestworld.com.sg



Annex C

Royalty Fee Documentation

技术进口合同数据表

中文 外文 中文 外 市 外 市 国 中	43003960 长沙百世。 CHANG S 湖南省 新加坡	rk License Agreer 026476 特威日用品贸易有		ED				
代码 中文 外文 省市 国別	43003960 长沙百世。 CHANG S 湖南省 新加坡	026476 特威日用品贸易有	限公司	ED				
中文 外文 省市 国別	43003960 长沙百世。 CHANG S 湖南省 新加坡	026476 特威日用品贸易有	限公司	ED				
外文 省市 国別	CHANG S 湖南省 新加坡			ED				
省市国別	CHANG S 湖南省 新加坡			ED				
国别	湖南省新加坡							
中文	△ ★ 川 田 →		新加坡					
	王夫世界有							
外文	BEST WORLD INTERNATIONAL LIMITED							
中文	长沙百世特威日用品贸易有限公司							
外文		The same of the sa	EI COMPANY LIMITE	=D				
	2016-01-		合同有效期					
			登记号/许可证号					
	入门费		0(万美	(- ·)				
Hs +E -12		提成年限						
以1定以	提成	提成基准	2-7	提成率				
		估计提成费总计	+	销售额				
				800.77(万美元)				
11131/1	7新加坡元)			1031(万新加坡元) 无				
	提成 1031(7		提成 提成基准 估计提成费总证 技术	提成 提成基准 估计提成费总计				

申请单位公章

售付汇记录:

外经贸主管部门公章

现:汇/顺江	THE RESIDENCE AND ADDRESS OF THE PERSON NAMED IN		
		设备费	银行签章
			1111111111111
	CONTRACTOR OF THE PARTY OF THE		
	现汇/购汇 市种	12个数	現社/购汇 币种 技术费 设备费





(181)湘国证00537407

纳税人识别号		填发日期: 年 2018	月 日 8 15 纳税人名称	税务机关: 国家利 世特威日用品贸易有限/	的
	, 003960264765 税 种	品目名称	税款所属时期	入(退)库日期	实缴(退)金额
20180815000037231	增值税	销售无形资产	2018-08-01至2018-08-31	2018-08-15	3,463,480.98
金额合计 (大写)		幸佰捌拾元零玖角捌分			¥3, 463, 480. 98
1 型 条 加 · · · · · · · · · · · · · · · · · ·		填 票 人马知遥	199号湘江世	敷税款正税代扣代缴长划 紀城富灣国际 6 栋 1 0 0 、分局)、原长沙市开福	1室 【区国家税务局税源





(181)湘国证 00537408

内税人识别号 914301 ₁	003960264765	2018 8	月 15 纳税人名称 长沙百	世特威日用品贸易有限公	务总局长沙市开福区税务 司
原凭证号	税种	品目名称	税款所属时期	入(退)库日期	实缴(退)金额
180815000038839 1	小业所得税	· 如税所得额 :	2018-08-15至2018-08-15	2018-08-15	5,772,468.30
额合计 (大写)	伍佰柒拾柒万贰仟肆何	百陆拾捌元 叁角	备注 (101) 神野 (1000)		¥ 5, 772, 4 68. 30
在稅专 / 章	税务 机 美 填 票 人 马知遥		(181) 湘税证00537408 正常申报代扣代缴税款正税代扣代缴长沙市开福区金泰路 199号湘江世纪城富湾国际6栋1001室 主管税务所(科、分局):原长沙市开福区国家税务局税源 管理三科被担缴额益益证F430105702000120BEST WORLD 手写N更RN及IONAL LIMITED		